article thumbnail

Dyadic expands Covid-19 licence with Rubic to bolster vaccine production in Africa

Pharmaceutical Technology

The expanded licence will include the development of vaccines and therapeutic proteins beyond Covid-19 for human and animal health markets in Africa. During the Covid-19 pandemic, vaccination rates of many countries in Africa were significantly trailing the rest of the world.

article thumbnail

Croda Pharma and BSI partner for vaccine adjuvant QS-21 production

Pharmaceutical Technology

Croda Pharma has entered a strategic collaboration deal with Botanical Solution Inc (BSI) to expedite the production of sustainable pharmaceutical-grade vaccine adjuvant QS-21. Croda Pharma and BSI will share their knowledge to bring QS-21 to market from quillaja Saponaria plant cell culture, which is made from the soap bark tree.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pfizer RSV vaccine gets off to fast start on market

Bio Pharma Dive

The pharma’s shot Abrysvo made over $300 million in sales during the first few months of its launch, and will be an important product to help offset declining COVID vaccine sales.

article thumbnail

EC grants marketing authorisation for GSK’s RSV vaccine Arexvy

Pharmaceutical Technology

The European Commission (EC) has granted marketing authorisation for GSK’s respiratory syncytial virus (RSV) vaccine, Arexvy, for adults aged 60 years and above. The vaccine is indicated for active immunisation to prevent RSV-related lower respiratory tract disease (LRTD) in older adults.

article thumbnail

SK Bioscience gains UK authorisation for SKYCovion Covid-19 vaccine

Pharmaceutical Technology

SK Bioscience has received marketing authorisation from the UK’s medicines and healthcare products regulatory agency (MHRA) for its Covid-19 vaccine, SKYCovion. The authorisation allows the distribution of the vaccine in Scotland, Wales and England.

article thumbnail

EC grants marketing authorisation for Takeda’s dengue vaccine

Pharmaceutical Technology

The European Commission (EC) has granted marketing authorisation for Takeda ’s Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) to prevent dengue in people aged four years and above. According to the results, the trial met the primary endpoint of overall vaccine efficacy by averting 80.2%

article thumbnail

EMA grants full marketing authorisation for AstraZeneca’s Covid-19 vaccine

Pharmaceutical Technology

The European Medicines Agency (EMA) has granted full marketing authorisation (MA) for AstraZeneca ’s Covid-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]). The vaccine initially received a conditional marketing authorisation (cMA) for use in the European Union (EU).